• Transplant Clinical Trials

    The following are current clinical trials at Lahey Hospital & Medical Center that are specifically related to transplantation. You also may view a complete listing of all of Lahey’s current clinical trials.

    Study   Objective   Contact  
     A 24 Month, Randomized, Controlled, Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants [LCID Study Number: 2014-032]    Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants   Principal Investigator(s): 
    Elizabeth A. Pomfret, MD, PhD

    For more information about this Research Study, call 781-744-8027

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos
     
     Study  Objective  Contact 
     A Multi-Center, Randomized, Prospective Open- Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin (HCIG) in Orthotopic Liver Transplant Recipients [LCID Study Number: 2014-023   This purpose of this study is to test the safety of different doses of the investigational therapy Hepatitis C Immune Globulin (HCIG) when given to patients with Hepatitis-C (HCV) who undergo liver transplantation   Principal Investigator(s):
    Fredric D. Gordon, MD

    For more information about this Research Study, call 781-744-8027

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos
     
    Study  Objective  Contact 
     A Prospective Investigation Of Quality Of Life In Live Liver Donors [LCID Study Number: 2001-019   Questionnaire study of quality of life in live liver transplant donors  Principal Investigator(s):
    Elizabeth A. Pomfret, MD, PhD

    For more information about this Research Study, call 781-744-8027

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos
          
     Study   Objective   Contact      
     A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration -controlled everolimus with reduced calcineurin inhibitor vs. mycophenolate with standard calcineurin inhibitor in de novo renal transplantation advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus based regiMen (TRANSFORM  Study to determine best use and doses for immunosuppressive agent everolimus in kidney transplant patients   Principal Investigator(s):
    Zeeshan Khawaja, MD

    For more information about this Research Study, call 781-744-8027

    Study Coordinator(s):
    Agnes P. Trabucco,
    Erick Marangos
     


     

     

  • Make An Appointment

    781.744.2500

    Jump to: